{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:42:58Z","timestamp":1791186178234,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016946","name":"Singulex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007658","name":"Baxter Healthcare Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014941","name":"Cytokinetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jacc.2021.11.027","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T15:17:16Z","timestamp":1643642236000},"page":"432-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin"],"prefix":"10.1016","volume":"79","author":[{"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.11.027_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.027_bib2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet. Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2021.11.027_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.11.027_bib4","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2021.","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2021.11.027_bib5","first-page":"215","article-title":"Biomarker-based risk prediction of incident heart failure in pre-diabetes and diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.11.027_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.05.007","article-title":"Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - a randomized placebo-controlled trial","volume":"166","author":"Neal","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.11.027_bib8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.027_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ahj.2013.02.029","article-title":"Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results","volume":"165","author":"Wu","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2021.11.027_bib10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1415921","article-title":"Troponin and cardiac events in stable ischemic heart disease and diabetes","volume":"373","author":"Everett","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.027_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc20-1889","article-title":"Insulin-like growth factor binding protein 7 predicts renal and cardiovascular outcomes in the canagliflozin cardiovascular assessment study","volume":"44","author":"Januzzi","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2021.11.027_bib12","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1001\/jama.2019.3471","article-title":"Resurgence in diabetes-related complications","author":"Gregg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.11.027_bib13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","article-title":"Serial measurement of high-sensitivity troponin i and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE trial","volume":"135","author":"Cavender","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.027_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamacardio.2016.3030","article-title":"Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: A secondary analysis of a randomized clinical trial","volume":"1","author":"Scirica","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.027_bib15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.2073","article-title":"Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium\u2013glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58","volume":"23","author":"Zelniker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.027_bib16","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","article-title":"Effects of canagliflozin on amino-terminal pro\u2013B-type natriuretic peptide: implications for cardiovascular risk reduction","volume":"76","author":"Januzzi","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.027_bib17","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.11.027_bib18","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","article-title":"Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial","author":"Nassif","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.027_bib19","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart\u00a0Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacc.2021.11.027_bib20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.027_bib21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.027_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.027_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.027_bib24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/eurheartj\/ehx511","article-title":"Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial","volume":"39","author":"Fitchett","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.11.027_bib25","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.027_bib26","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ejhf.2135","article-title":"Prevention of heart failure events with sodium\u2013glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk","volume":"23","author":"Bhatia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2021.11.027_bib27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2021.11.027_bib28","doi-asserted-by":"crossref","first-page":"A15701","DOI":"10.1161\/circ.142.suppl_3.15701","article-title":"Relationship between cardiac biomarkers and\u00a0major adverse cardiovascular events in DECLARE-TIMI 58 (abstr)","volume":"142","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.027_bib29","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.11.027_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.11.027_bib31","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.athoracsur.2015.11.024","article-title":"Adjust for multiple comparisons? It\u2019s not that simple","volume":"101","author":"Althouse","year":"2016","journal-title":"Ann Thorac Surg"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721082516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721082516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:47:19Z","timestamp":1760017639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721082516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0735109721082516"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.027","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}